Literature DB >> 28640521

PET/MRI for evaluating subclinical inflammation of ulcerative colitis.

I-Lun Shih1, Shu-Chen Wei2, Rouh-Fang Yen3, Chin-Chen Chang1, Chi-Lun Ko3, Been-Ren Lin4, Chia-Tung Shun5, Kao-Lang Liu1, Jau-Min Wong2, Yeun-Chung Chang1.   

Abstract

PURPOSE: To explore the utility of integrated positron emission tomography (PET) / magnetic resonance imaging (MRI) for evaluating subclinical inflammation in patients with ulcerative colitis (UC).
MATERIALS AND METHODS: This prospective study was approved by the Institutional Review Board and informed consent was obtained. Between November 2015 and April 2016, 19 consecutive patients with UC in clinical remission were enrolled. These patients underwent 18F-fluorodeoxyglucose PET/MRI (3T) and colonoscopy. Serum high-sensitivity C-reactive protein (hs-CRP) and fecal calprotectin (FC) levels were also obtained. The findings of colonoscopy were graded using the Mayo endoscopic subscore. Quantitative (minimum apparent diffusion coefficient [ADCmin ] and maximum standardized uptake value [SUVmax ]), semiquantitative, and qualitative parameters of PET/MRI were evaluated and correlated with colonoscopic findings.
RESULTS: In per-segment analysis, ADCmin was significantly lower and SUVmax and ratio of SUVmax to ADCmin were significantly higher in the colonic segments with active inflammation (Mayo endoscopic subscore ≥2) (P < 0.05). Qualitative MRI score, PET activity grade, and PET/MRI score were also significantly higher in the colonic segments with active inflammation (P < 0.05). Among these parameters, the ratio of SUVmax to ADCmin exhibited the highest area under the receiver operating characteristic curve (AUC) (0.763). In per-patient analysis, the AUC of PET activity grade was 0.778, higher than those of hs-CRP (0.589) and FC (0.722). Using a combined index of FC and PET, an even higher AUC (0.867) was achieved.
CONCLUSION: PET/MRI is a potentially useful tool in identifying subclinical inflammation in patients with UC. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:737-745.
© 2017 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  inflammatory bowel disease; magnetic resonance imaging; positron emission tomography; ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 28640521     DOI: 10.1002/jmri.25795

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

1.  Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease.

Authors:  Onofrio Antonio Catalano; Vincent Wu; Umar Mahmood; Alberto Signore; Mark Vangel; Andrea Soricelli; Marco Salvatore; Debra Gervais; Bruce R Rosen
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

2.  18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial.

Authors:  Yan Li; Benedikt Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Anna Katharina Koch; Ole Martin; Ken Herrmann; Hendrik Juette; Andrea Tannapfel; Jost Langhorst
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-24       Impact factor: 9.236

3.  Novel non-invasive assessment of upper airway inflammation in obstructive sleep apnea using positron emission tomography/magnetic resonance imaging.

Authors:  Oren Cohen; Mira M John; Audrey E Kaufman; Vaishnavi Kundel; Omar Burschtin; Samira Khan; Zahi Fayad; Venkatesh Mani; Neomi A Shah
Journal:  Sleep Breath       Date:  2021-08-26       Impact factor: 2.655

4.  Comparison of 18F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis.

Authors:  Yan Li; Michael Khamou; Benedikt Michael Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Johannes Haubold; Anna Katharina Koch; Nils-Martin Bruckmann; Lino Morris Sawicki; Ken Herrmann; James Hunter Boone; Jost Langhorst
Journal:  Br J Radiol       Date:  2020-06-24       Impact factor: 3.039

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.